The case for & against
Bull & Bear analysis
Bearish
NeurAxis, Inc. (NASDAQ: NRXS) specializes in innovative neuromodulation therapies, particularly targeting pediatric gastrointestinal disorders with its primary product, IV STEM. Recently, the company has been focusing on expanding its market presence through the introduction of the Category 1 CPT code for reimbursement. This code is expected to facilitate access to treatment, making NeurAxis a key player in the therapeutic landscape, especially in engaging healthcare payers and expanding their overall market reach.
Bull says
- ↑Q1 2026 revenue hit $1.6M (+80% YoY), proving strong demand
- ↑Category 1 CPT code effective Jan 2026 streamlines billing and reimbursement
- ↑Added 45M covered lives via major insurer, driving revenue scalability
- ↑Burn rate trimmed to $1.2M/quarter with $7.1M cash runway
- ↑Gross margin expanded to 86.4% from 84.4% on better payer mix
- ↑Positive momentum factors suggest growing investor interest
Bear says
- ↓Severely negative earnings yield and weak profitability risk returns
- ↓Q1 net loss of $1.8M persists despite a 23% YoY reduction
- ↓Operating expenses rose 3% to $3.1M, pressuring future margins
- ↓Expansion relies on securing payer agreements, which remain uncertain
- ↓Complex CPT code rollout and commercialization execution pose delays
- ↓Elevated leverage risk and weak factor profile limit upside
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-14-2026neutral
Transcript signals
Bull points
- We are continuing our strong momentum, which began in the third quarter of 2024. This momentum has continued here into the second quarter of 2025. The good news is we are only in the early innings of our ramp, as we expect the number of covered lives to continue to grow, and our Cat 1 CPT code goes effective on January 1st of 2026.
- Given our current cost structure, our goal as a company to reach cash flow break-even is achievable.
- Unit sales increased approximately 46% due to growth from patients with full insurance reimbursement coverage and the company's financial assistance program that provides discounts to patients without insurance coverage.
Bear points
- Excluding the one-time legal settlement charge, the company's operating loss would have improved 9% compared to Q1 of 24.
- Operating loss in the first quarter of 25 was 2.3 million, an increase of 25% compared to a $1.8 million loss in the first quarter of 2024.
- Our net loss in the first quarter was $2.3 million, an increase of 8% compared to $2.1 million in the first quarter of 24.
Read full transcript analysis ›